

## "By the end of 2020, 33% of global clinical trials will be disrupted"- Unmesh Lal

23 July 2020 | Views

**Unmesh Lal, Transformational Health Industry Principal, Frost & Sullivan reveals predictions for the global healthcare industry post COVID-19**

"While the life sciences segment seems to be surviving and thriving, in certain scenarios, medical technologies and imaging are expected to be hit the hardest. Elective procedures being on hold and delayed or prolonged procurement of capital equipment will have a negative impact on revenue, from \$413.9 billion to \$377.1 billion for medical devices and from \$31.5 billion to \$18.1 billion for imaging equipment. Additionally, with telehealth transforming care delivery and health IT enhancements in analytics and interoperability, digital health will continue to thrive at a growth rate of 7.9% in 2020.

- The KSA, UAE and Indian telehealth markets have reached a tipping point with growth of more than 200% during the pandemic. Virtual consultations by healthcare professionals will become the mainstream care delivery model post-pandemic. However, reimbursement, training physicians, and platform scalability will be the key to recalibrating telehealth.
- Informatics and artificial intelligence (AI) solutions addressing workflow automation and operational analytics will witness 100% growth in 2020. For instance, GE Healthcare's industry-first, FDA-cleared Critical Care Suite AI tool will help radiologists prioritize critical cases. The resumption in imaging for the backlog of elective procedures in Q3 and Q4 will result in teleradiology and AI-based solutions gaining from new investments. Scale-up in capacity, flexible payment options, and redistribution of the workload will accelerate partnerships.
- The United States will have an excess of 100,000 ventilators, while Western Europe will purchase another 30,000 to 50,000 ventilators through the end of 2020. This uneven distribution across regions will redefine non-hospital and home critical care models, while embedded analytics systems will revive the mature monitoring devices segment post-pandemic. Resmed has launched a remote monitoring solution for ventilators in the US and Europe through its cloud-based AirView™ platform for homecare.
- Traditional models of in vitro diagnostics (IVD) testing in a healthcare setting are unable to meet unprecedented demand. By the end of 2020, the \$5 billion PoCT infectious diseases market will drive the impending change in service

models, with alternate testing sites like pharmacies becoming permanent ecosystem participants. CVS and Walgreens have begun building the infrastructure to offer IVD testing at their locations.

- By the end of 2020, 33% of global clinical trials will be disrupted, putting \$3 billion in new product revenues at risk. Disrupted clinical trials and the subsequent delay in drug launches will pave the way for fully virtual trials, and hybridization of patient recruitment, retention, and monitoring will become all-pervasive."

**Unmesh Lal, Transformational Health Industry Principal, Frost & Sullivan**